AMBI Promotes Jon De La Harpe, Ph.D., to Senior Vice President, Commercial Operations.

Business Editors

PURCHASE, N.Y.--(BW HealthWire)--April 18, 2000

Newly Created Position Reflects Company's Growth

and Plans for Continued Expansion

AMBI Inc. (Nasdaq: AMBI) named Jon de la Harpe, Ph.D., 54, to the newly created position of senior vice president, commercial operations, reporting directly to Fredric D. Price, AMBI's president and chief executive officer. All AMBI business units and departments, with the exception of legal and finance, will report to Dr. de la Harpe, who has served as the company's vice president, technical operations since 1998.

Mr. Price said, "During the past two years, AMBI has undergone a dramatic transformation into a profitable, cash-generating, growing company focused on the development and marketing of proprietary nutrition products. We now have three business units -- Ingredients, Direct Response, and Retail -- and have identified the need for a senior executive to coordinate marketing, sales, product development, process development, research and manufacturing activities on a day-to-day basis.

"Jon de la Harpe is the ideal executive to assume this responsibility, given his deep scientific knowledge, his extensive experience in increasingly important research, manufacturing and technical operations positions at the company, as well as his close working relationship with me. During an 11-year career at AMBI, Jon has been an important part of the company's transformation into a proprietary nutrition products organization. Given our plans to expand through both organic growth and acquisitions, we need the skill set that Jon brings to ensure that the company's commercial operations function smoothly."

Mr. Price added, "With Jon's promotion, my efforts will be concentrated on business and market development, acquisitions and joint-venture opportunities, investor and financial relations activities, and overseeing the recently announced NutritionU.com business."

Dr. de la Harpe said, "AMBI has marshaled the intellectual property, human resource and financial assets necessary for organization expansion. Each of the three business units has opportunities for growth from our own product development programs and through acquisitions as well as third-party ventures. I am excited about this new management opportunity to assist in the company's emergence into an important multi-channel marketer of unique, science-based proprietary nutrition products."

Dr. de la Harpe has been on the staff at AMBI since 1989, holding such positions as group leader, analytical and biochemistry; program manager; senior manager, product development; director of technical operations; and vice president, technical operations. Prior to joining AMBI, he held positions as post-doctoral fellow and later research associate at The Rockefeller University, and as assistant professor at Cornell University Medical College. During this period, Dr. de la Harpe also held positions as a visiting scientist at Genentech Inc. and scientist at the Friedrich Miescher Institute in Basel, Switzerland. He holds a B.Sc. (Hons) and Ph.D. from the University of Cape Town, South Africa.

AMBI develops and markets proprietary nutrition products.

This press release may contain certain forward-looking statements. The words "believe," "expect," "anticipate" and other similar expressions generally identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based largely on the company's current expectations and are subject to a number of risks and uncertainties, including without limitation: the effect of the expiration of patents; regulatory issues; uncertainty in the outcomes of clinical trials; changes in external market factors; changes in the company's business or growth strategy or an inability to execute its strategy due to changes in its industry or the economy generally; the emergence of new or growing competitors; various other competitive factors; and other risks and uncertainties indicated from time to time in the company's filings with the Securities and Exchange Commission, including its Registration Statement on Form S-3, the Prospectus dated June 10, 1999, and its Form 10-K for the year ended June 30, 1999. Actual results could differ materially from the results referred to in the forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements contained in this press release will in fact occur. Additionally, the company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that may bear upon forward-looking statements.